In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report), with a price target of $4.00. The company’s shares closed today at $2.60.
Zimmerman covers the Healthcare sector, focusing on stocks such as Stryker, Glaukos, and Zimmer Biomet Holdings. According to TipRanks, Zimmerman has an average return of 8.3% and a 44.22% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Organogenesis Holdings with a $3.50 average price target.
See today’s best-performing stocks on TipRanks >>
ORGO market cap is currently $341.4M and has a P/E ratio of 34.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Read More on ORGO:
- Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Organogenesis slides after reporting Q2 results, removing FY guidance
- Organogenesis price target lowered to $4 from $10 at BTIG
- Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
- ORGO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
